Dr. Geoffrey Shapiro on the Role of CDK2 in Multiple Breast Cancer Types

Geoffrey Shapiro, MD, PhD, director, Early Drug Development Center, Dana Farber, discusses the role of cyclin-dependent kinase (CDK4) in some breast cancer subtypes and the lack of targeted agents in triple-negative breast cancer.

Geoffrey Shapiro, MD, PhD, director, Early Drug Development Center, Dana Farber, discusses the role of cyclin-dependent kinase (CDK4) in some breast cancer subtypes and the lack of targeted agents in triple-negative breast cancer. Shapiro says CDK4 plays a role in the proliferation of estrogen-receptor positive breast cancer and HER-2 positive breast cancer cells, though triple-negative breast cancer is still an enigma.